Skip to main content
. 2021 Oct 8;9(10):e002836. doi: 10.1136/jitc-2021-002836

Figure 3.

Figure 3

Increased coexpression of PD-L1/TIM3 or PD-L1/TIGIT predicted poor OS of patients with ESCC. Kaplan-Meier (left panel) and restricted mean survival time (RMST) (right panel) curves were plotted based on the different groups of mRNA PD-L1/TIM3 (A) or PD-L1/TIGIT (B) in the training cohorts. The results of Kaplan-Meier (left panel) and RMST (right panel) curves of protein PD-L1/TIM3 (C) or PD-L1/TIGIT (D) were confirmed in the validation cohorts. Group I: PD-L1loTIM3lo or PD-L1 (−)/TIM3 (−); group II: PD-L1hiTIM3lo or PD-L1loTIM3hi, PD-L1 (+)/TIM3 (−) or PD-L1 (−)/TIM3 (+); group III: PD-L1hiTIM3hi or PD-L1 (+)/TIM3 (+); group IV: PD-L1loTIGITlo or PD-L1 (−)/TIGIT (−); group V: PD-L1hiTIGITlo or PD-L1loTIGIThi, PD-L1 (+)/TIGIT (−) or PD-L1 (−)/TIGIT (+); and group VI: PD-L1hiTIGIThi or PD-L1 (+)/TIGIT (+). ESCC, esophageal squamous cell carcinoma; OS, overall survival; PD-L1, programmed cell death 1 ligand 1; TIGIT, T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain; TIM3, T-cell immunoglobulin and mucin-domain-containing-3.